stockrow
Friday 6 November 2026
Export ORKA’s income statement to Excel — free account
Oruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
102.68
6.66
+6.94%
Follow ORKA
Alert me
Oruka Therapeutics, Inc. (ORKA) Net income
Oruka Therapeutics, Inc.'s net income for fiscal 2025 was −$105.4M, compared with −$83.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$132.9M. Over the past ten years it has ranged from −$105.4M (fiscal 2025) to −$5.3M (fiscal 2023) — the current reading is the lowest in ten years. Oruka Therapeutics, Inc. ranks 464th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$105.4M | — |
| FY2024 | −$83.7M | — |
| FY2023 | −$5.3M | — |
| FY2022 | −$9.9M | — |
| FY2021 | −$19.3M | — |
| FY2020 | −$9.7M | — |
| FY2019 | −$5.5M | — |
| FY2018 | −$7.9M | — |
| FY2017 | −$18.5M | — |
| FY2016 | −$16.4M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$41.2M | — |
| Mar 2026 | −$31.8M | — |
| Dec 2025 | −$29.6M | — |
| Sep 2025 | −$30.3M | — |
| 42 more quarters | Free account |
Against its own ten years
Low −$105.4M
High −$5.3M
Ten-year median
−$11.4M
Current reading's percentile
9
Net income against peers
| Company | Net income |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $51.5M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$77.6M |
| ORKA Oruka Therapeutics, Inc. | −$132.9M |
| AXSM Axsome Therapeutics, Inc. compare | −$157.3M |
| CGON CG Oncology, Inc. compare | −$224.4M |
| KOD Kodiak Sciences Inc. compare | −$242.0M |
| IMVT Immunovant, Inc. compare | −$538.2M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$565.2M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$903.9M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item